摘要
目的 观察重组人干扰素-α1b治疗毛细支气炎的疗效.方法 将160例毛细支气管炎患儿随机分为两组,两组均给予常规治疗.此外观察组加用重组人干扰素-α1b治疗,对照组给予利巴韦林治疗.观察两组患儿临床症状体征改善情况及消失的天数.结果 两组治疗后,患儿体温、喘憋、咳嗽、肺部啰音改善比较,差异均有统计学意义（t分别为1.832、2.761、2.650、2.526,均P＆lt;0.05）.结论 重组人干扰素-α1b治疗毛细支气管炎能明显缩短发热、咳嗽、喘憋、肺部啰音消失的时间,疗效优于利巴韦林.
Objective To observe therapeutic effect of recombinant human interferon -edb for bronchioritis of children. Methods 160 children with bronchioritis were divided into two group randomly ： treatment group （ n = 80 ） and control group （ n = 80 ）. All children received routine gasping-relieving treatment. Then the children in the treatment group were further given intramuscularly recombinant human interferon-crib and those children in the control group were further given intravenously ribavirin. The improvement and disappearance days of signs and symptoms of the children in the two groups were observed and compared. Results Between the two grotips there were significant differences in disappearance days of symptoms and signs such as fever, gasping and feeling oppressed, coughing and pulmonany rales （t = 1. 832, 2. 761, 2.650, 2. 526 respectively, all P 〈 0.05 ）. Conclusion For treatment of bronchioritis, recombinant human interferon -crib can significantly shorten lengths of fever, coughing, gasping and disappearance of pulmonany rales ,＇ and therapeutic effect is superior to ribavirin.
出处
《中国妇幼健康研究》
2010年第5期657-658,共2页
Chinese Journal of Woman and Child Health Research
关键词
重组人干扰素-α1b
毛细支气管炎
利巴韦林
疗效观察
recombinant human interferon-cdb
bronchiolitis
ribavirin
clinical observation of therapeutic effect
